Oncotelic Therapeutics, Inc.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Oncotelic Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of anti-vascular therapeutics for patients with cancer and sight-threatening eye diseases. It also develops OT-101 for various cancers and COVID-19, Artemisinin for COVID-19 and AI technologies for clinical development and manufacturing. The company was founded in 1988 and is headquartered in Agoura Hills, CA.

AGOURA HILLS, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) ( OTCQB:OTLC ), developer of treatments for rare and orphan indications, including Parkinson Disease and DIPG, today announced that the Company will have two poster presentations at the upcoming 2022 Society for Neuro-Oncology (SNO) Annual Meeting on November 16-20, 2022, Tampa Bay, Florida.

Oncotelic Presenting Data for OT101 Against Diffuse Intrinsic Pontine Glioma (DIPG) at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting

AGOURA HILLS, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“ Oncotelic ” , “ We ” or the “ Company ”) (OTCQB: OTLC ) today announced financial results for the three months ended June 30, 2022 (“Q2 2022”) as compared to the three months ended June 30, 2021 (“Q2 2021”). The financial results are based on the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 22, 2022.

ONCOTELIC REPORTS Q2 2022 COMPARED TO Q2 2021 FINANCIAL RESULTS

AGOURA HILLS, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including Parkinson Disease and various cancers, today announced that the Company will be participating at Biotechgate Digital Partnering – a business development & licensing event - Aug 29 - Sep 2, 2022. An updated investor slide deck will be available at our website after the event.

Oncotelic Participating at Biotechgate Digital Partnering

AGOURA HILLS, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including Parkinson Disease and various cancers, today announced that the Company presentation at 7th JCA-AACR Special Joint Conference (July 8-10, 2022) is now available at https://www.oncotelic.com/wp-content/uploads/2022/07/JCA-2022.pptx.pdf and https://www.youtube.com/watch?v=D9h7ExvUUVs.

Oncotelic Announces Presentation of P001- OT-101 Phase 1/2 Trial in Pancreatic Cancer

AGOURA HILLS, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including Parkinson Disease and various cancers, today announced that the Company presentation at BIO International Convention is now available at https://www.oncotelic.com/wp-content/uploads/2022/06/BIO-2022-digital-slides.pdf.

Oncotelic Provides Update on OT-101 at the 2022 BIO International Convention

AGOURA HILLS, Calif., May 25, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), a developer of treatments for rare and orphan indications, including Parkinson Disease and various cancers, today announced the clearance of the Phase 2 clinical trial protocol for mesothelioma after filing the protocol to the Food and Drug Administration. Oncotelic is initiating a Phase 2 Investigator Initiated Study (IIS) clinical trial in patients with metastatic plural mesothelioma (MPM) in collaboration with Merck who is supplying pembrolizumab for the study.

Oncotelic Therapeutics Receives FDA Clearance for Phase 2 Clinical Trial of OT-101/Pembroluzimab Combination for Mesothelioma (M201)

AGOURA HILLS, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“ Oncotelic ” , “ We ” or the “ Company ”) ( OTCQB: OTLC ) today announced financial results for the three months ended March 31, 2022 (“Q1 2022”) as compared to the three months ended March 31, 2021 (“Q1 2021”), an update on its product and therapeutic development initiatives and other corporate updates. The financial results were based on the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 23, 2022.

ONCOTELIC PROVIDES Q1 2022 FINANCIAL RESULTS COMPARED TO Q1 2021, PRODUCT DEVELOPMENT INITIATIVES AND CORPORATE UPDATE

AGOURA HILLS, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“ Oncotelic ” , “ We ” or the “ Company ”) (OTCQB: OTLC ) today announced financial results for the full year ended December 31, 2021 (“FY 202 1”) as compared to the full year ended December 31, 2020 (“FY 2020”), an update on its product and therapeutic development initiatives and other corporate updates. The financial results were based on the 2021 Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 15, 2022.

ONCOTELIC PROVIDES YE 2021 FINANCIAL RESULTS COMPARED TO YE 2020, PRODUCT DEVELOPMET INITIATIVES AND CORPORATE UPDATE

AGOURA HILLS, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“ Oncotelic ” or the “Company”) (OTCQB :OTLC ), issued the following shareholder letter today.

Letter to Oncotelic Shareholders on the Recently Completed Joint Venture Transaction with Dragon Overseas Capital Limited

AGOURA HILLS, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“ Oncotelic ” or the “Company”) ( OTCQB:OTLC ), a leading developer of TGF-β therapeutics for oncology and virology, today announced that it will present new studies on its TGF- β program at the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13 in New Orleans, Louisiana.

Oncotelic to Present New Studies on its TGF-β Program at the American Association for Cancer Research (AACR) Annual Meeting 2022

AGOURA HILLS, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“ Oncotelic ” or the “Company”) ( OTCQB:OTLC ), and Marcus Evans are proud to announce Dr Anthony E. Maida, Chief Clinical Officer – Translational Medicine for Oncotelic, Inc. as a speaker at the upcoming annual Evolution Summit taking place in Los Angeles this month.

Dr. Anthony E. Maida will be presenting at the Marcus Evans Evolution Summit

AGOURA HILLS, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ( “ Oncotelic ” or the “ Company ” ) ( OTCQB:OTLC ) , a leading developer of TGF-β therapeutics for oncology and virology, today announced that Dr. Vuong Trieu, Oncotelic Chairman and CEO, will be presenting at MedInvest Pharmaceutical and Biotechnology Investor Conference (the “Conference”), from March 28 - April 1, 2022.

Oncotelic Presenting at MedInvest Pharmaceutical and Biotechnology Investor Conference

AGOURA HILLS, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ( “ Oncotelic ” or the “ Company ” ) (OTCQB:OTLC) , a leading developer of TGF-β therapeutics for oncology and virology, today announced that Dr. Vuong Trieu, Oncotelic Chairman and CEO, will be presenting at MedInvest Pharmaceutical and Biotechnology Investor Conference (the “Conference”), from March 28 - April 1, 2022.

Oncotelic Presenting at BiotechGate Digital Partnering

AGOURA HILLS, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (" Oncotelic " or the "Company") ( OTCQB:OTLC ) , a leading developer of TGF-β therapeutics for oncology and virology, today announced that it has submitted a clinical study protocol to the United States Food and Drug Administration (“US FDA”) for the initiation of a Phase 1 Clinical Trial for CA4P, the Company's Vascular Disrupting Agent, in combination with Anti-PD-1 (pembrolizumab) as a treatment for patients with Melanoma.

Oncotelic Initiates Phase 1 Trial Evaluating CA4P in Combination with Pembrolizumab for Melanoma

AGOURA HILLS, Calif., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") ( OTCQB:OTLC ) , a leading developer of TGF-β therapeutics for oncology and virology, today announced that it has performed mutational analysis of SARS-CoV-2 and demonstrated that the open reading frames 8 (“ORF8”) is potentially driving the evolution of the Delta and the Omicron variants. ORF8 protein is abundantly secreted in COVID patients. Fatality in hospital patients is associated with higher serum levels of ORF8. ORF8 is one of the least well conserved and most variable parts of the SARS-CoV-2 genome.

News for Oncotelic Therapeutics, Inc. Stock (OTLC)